We are live on ! Find out more
AP

AtonRa Partners Portfolio holdings

AUM $50.2M
1-Year Est. Return 47.76%
This Fund
S&P 500
This Quarter Est. Return
+12.94%
1 Year Est. Return
+47.76%
3 Year Est. Return
+48.32%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$273M
AUM Growth
+$48.5M
Cap. Flow
+$27.1M
Cap. Flow %
9.94%
Top 10 Hldgs %
21.2%
Holding
121
New
13
Increased
46
Reduced
53
Closed
9

Top Buys

Rank Stock Value
1
SEDG icon
SolarEdge
SEDG
+$3.1M
2
MRVL icon
Marvell Technology
MRVL
+$3.02M
3
VEEV icon
Veeva Systems
VEEV
+$2.97M
4
QTRX icon
Quanterix
QTRX
+$2.96M
5
SOFI icon
SoFi Technologies
SOFI
+$2.56M

Top Sells

Rank Stock Value
1
GH icon
Guardant Health
GH
+$2.98M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$2.86M
3
ILMN icon
Illumina
ILMN
+$2.18M
4
RGNX icon
Regenxbio
RGNX
+$2.05M
5
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$1.77M

Sector Composition

Rank Sector Weight
1 Technology 44.35%
2 Healthcare 32.32%
3 Financials 8.79%
4 Industrials 7.11%
5 Consumer Discretionary 3.86%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DCT
101
DELISTED
Duck Creek Technologies, Inc. Common Stock
DCT
$913K 0.33%
20,986
+2,634
+14% +$107K
BIIB icon
102
Biogen
BIIB
$29.9B
$912K 0.33%
2,633
-134
-5% -$40.6K
EBS icon
103
Emergent Biosolutions
EBS
$375M
$889K 0.33%
14,114
-1,361
-9% -$87.4K
MCRB icon
104
Seres Therapeutics
MCRB
$48M
$843K 0.31%
1,768
+680
+63% +$287K
GOCO
105
DELISTED
GoHealth
GOCO
$841K 0.31%
5,001
-3,505
-41% -$614K
LU icon
106
Lufax Holding
LU
$1.2B
$811K 0.3%
17,939
+1,560
+10% +$78.6K
CELL
107
DELISTED
PhenomeX Inc. Common Stock
CELL
$786K 0.29%
+17,551
New +$814K
FSLY icon
108
Fastly Inc
FSLY
$3.17B
$725K 0.27%
12,160
+125
+1% +$7.1K
NSTG
109
DELISTED
NanoString Technologies, Inc.
NSTG
$692K 0.25%
+10,677
New +$678K
GWRE icon
110
Guidewire Software
GWRE
$11.5B
$682K 0.25%
6,046
+495
+9% +$51.5K
NRIX icon
111
Nurix Therapeutics
NRIX
$2.43B
$626K 0.23%
+23,611
New +$693K
AMWL icon
112
American Well
AMWL
$181M
$377K 0.14%
1,497
+54
+4% +$15.6K
BMRN icon
113
BioMarin Pharmaceuticals
BMRN
$11.5B
– –
-7,429
Closed -$561K
ILMN icon
114
Illumina
ILMN
$29.4B
– –
-5,829
Closed -$2.18M
IONS icon
115
Ionis Pharmaceuticals
IONS
$9.35B
– –
-20,146
Closed -$906K
REGN icon
116
Regeneron Pharmaceuticals
REGN
$68.8B
– –
-2,067
Closed -$978K
RGNX icon
117
Regenxbio
RGNX
$623M
– –
-60,033
Closed -$2.05M
VRTX icon
118
Vertex Pharmaceuticals
VRTX
$121B
– –
-13,319
Closed -$2.86M
CBAY
119
DELISTED
Cymabay Therapeutics
CBAY
– –
-111,525
Closed -$506K
PFPT
120
DELISTED
Proofpoint, Inc.
PFPT
– –
-9,347
Closed -$1.18M
1 2 3 4
5

Similar funds

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
SC
Sonen Capital San Francisco, California $52.7M AUM 25.58% 1-Year Est. Return
AOGP
Addition One General Partner New York $45.7M AUM
ACJ
Autonomy Capital (Jersey) St. Helier, Jersey $54.8M AUM 37.27% 1-Year Est. Return
UFG
United Fire Group Cedar Rapids, Iowa $55M AUM 6% 1-Year Est. Return
KC
Kellner Capital New York $55.5M AUM 88.05% 1-Year Est. Return
P
Pariax Newport Beach, California $44.3M AUM 12.57% 1-Year Est. Return
AMC
AKKR Management Company Menlo Park, California $42.5M AUM 123.1% 1-Year Est. Return

AtonRa Partners's Q2 2021 Portfolio in Review

As of Q2 2021, AtonRa Partners held 121 positions worth $273M, up 22% from $224M the previous quarter. Its ten largest holdings account for 21% of the portfolio.

AtonRa Partners deployed $27.1M of net new capital in Q2 2021, opening 13 new positions and adding to 46 existing holdings. Its largest new stake was Marvell Technology: 61,809 shares worth $3.6M.

By sector, the portfolio is most concentrated in Technology at 44% of assets, up from 41% a quarter earlier, followed by Healthcare and Financials.

On the sell side, the largest reduction was Guardant Health, an estimated $2.98M trimmed.

  • AtonRa Partners's largest Q2 2021 buy was Marvell Technology: 61,809 shares worth $3.6M.
  • AtonRa Partners added most to SolarEdge in Q2 2021, an estimated $3.1M increase.
  • AtonRa Partners's biggest Q2 2021 reduction was Guardant Health, cutting an estimated $2.98M.
  • AtonRa Partners fully exited Vertex Pharmaceuticals in Q2 2021, selling an estimated $2.86M.
  • AtonRa Partners's ten largest holdings make up 21% of its $273M portfolio in Q2 2021.
  • AtonRa Partners opened 13 new positions and closed 9 in Q2 2021.
  • AtonRa Partners's portfolio value rose 22% quarter-over-quarter to $273M.

Based on AtonRa Partners's 13F filing for Q2 2021, filed 12 Aug 2021.